Early Signs of PML in Tysabri Patients: What to Watch For

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

General Health Context and Risk Communication

If you or a loved one is taking Tysabri, recognizing the earliest signs of progressive multifocal leukoencephalopathy (PML) can be critical for timely intervention. The medical community has long emphasized that early detection of PML improves outcomes, yet many patients are unaware of the subtle initial symptoms. This page provides a monitoring guide for follow-up tests and clinical exams used to detect PML early.

Tysabri and PML: A Medical Overview

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The prognosis for patients who develop PML while on Tysabri is poor, with the condition often leading to permanent disability or death. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and post-marketing surveillance. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks, and both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prognosis for PML is grim. The FDA label notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This means that even if a patient survives the acute infection, they are likely to suffer permanent neurological deficits. The damage caused by the JC virus is typically irreversible, as it destroys the myelin-producing cells in the brain. While some patients may experience partial recovery, the condition is generally considered permanent. The severity of disability depends on the extent of brain damage and the speed of diagnosis and intervention.

Risk Factors and Monitoring for PML

Several risk factors increase the likelihood of developing PML in Tysabri-treated patients. These include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA label emphasizes that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has also been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. The FDA advises that patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The FDA has mandated a boxed warning, which is the strongest warning the agency can require. Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients are informed of the risks and that healthcare providers monitor for signs of PML. Despite these measures, the risk remains, and patients must be vigilant. The FDA label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI dosing immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Permanent Nature of PML and Prognosis

In summary, PML from Tysabri is a permanent and often fatal condition. The prognosis is poor, with most patients experiencing severe disability or death. The risk is highest in patients with anti-JCV antibodies, those on long-term therapy, and those with prior immunosuppressant use. While the FDA has implemented strong warnings and a restricted distribution program, the risk cannot be eliminated. Patients and healthcare providers must remain vigilant for early signs of PML to improve the chances of a better outcome, though even with early intervention, permanent damage is likely. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is Progressive Multifocal Leukoencephalopathy from Tysabri permanent?

Yes, PML from Tysabri is generally considered permanent. The JC virus destroys myelin-producing cells in the brain, leading to irreversible neurological damage. While some patients may experience partial recovery, most suffer severe disability or death. The FDA label states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

How long after starting Tysabri can PML occur?

In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML has also been reported after discontinuation, so monitoring for at least six months post-treatment is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.